Developing iPSC-Derived Allogeneic Immune Therapies
In collaboration with George Daley, M.D, Ph.D. and Boston Children’s Hospital, ElevateBio established a new company to develop off-the-shelf immune therapies derived from induced pluripotent stem cells (iPSCs). The company is founded upon a novel differentiation process that develops iPSCs into mature immune cells, which was detailed in a peer-reviewed publication in Cell Stem Cell. This NewCo is enabled by our iPSC and gene editing technologies and scale-up manufacturing capabilities to develop a broad pipeline of iPSC-derived therapies.
Learn MoreAdvancing the Discovery and Development of Regenerative Medicines with CIRM
ElevateBio partnered with the California Institute for Regenerative Medicine (CIRM) to develop iPSC-derived therapeutics. Through the collaboration, we are providing academic institutions and biopharmaceutical companies access to our integrated ecosystem of iPSC lines, vector technology, process development and manufacturing capabilities to accelerate the discovery and development of cell and gene therapies.
Learn MoreManufacturing Cell & Gene Therapies with Research Institutes
ElevateBio and Massachusetts General Hospital (MGH) formed a 10-year alliance agreement to provide MGH with preferred access to our BaseCamp® process development and manufacturing facility in Waltham, Mass. for development and production of cell and gene therapies developed at MGH.
Learn MoreTranslating Research into Life-Changing Treatments
ElevateBio and Boston Children’s Hospital entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s. The collaboration enables ElevateBio and Boston Children’s to form multiple cell and gene therapy companies together while providing researchers access to our enabling technologies, manufacturing capabilities and leading expertise.
Learn More
